Quantcast

Actinium reaches milestone, enrols half of patients to test Iomab-B for Leukemia

Actinium Pharmaceuticals underlines half of patients treated in the pivotal Phase 3 SIERRA testing Iomab-B in Elderly Relapse Refractory Acute Myeloid Leukemia is the only randomized Phase 3 trial that offers BMT or bone marrow transplant as an option for older patients with active, relapsed or refractory AML or acute myeloid leukemia.

Read more

Qu Biologic’s trial shows CD symptoms can be improved with activating immune system

Qu Biologics’s first randomized-placebo controlled trial (RCT) resulst, for moderate-to-severe Crohn’s disease (CD) was accepted for publication in Frontiers in Medicine, an open-access peer-reviewed medical journal, as it showed that clinical symptoms of CD can be improved with an immunomodulatory treatment that functions to activate instead of suppress the immune system.

Read more

PCSK9is shown to lower improve cardiovascular outcomes, many rejected by their insurance plan

New research from the FH Foundation highlights that individuals at high risk for cardiovascular events, including those with familial hypercholesterolemia (FH) or atherosclerotic cardiovascular disease (ASCVD), experienced more heart attacks, strokes and other cardiovascular events when they were unable to obtain their prescribed PCSK9 inhibitor (PCSK9i), a cholesterol-lowering treatment.

Read more